Brentuksimab vedotin (Brentuximab vedotin)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antineoplastic agents - monoclonal antibodies

Included in the formulation
  • Adzetris®
    lyophilizate d / infusion 
    Takeda Pharma A / S     Denmark
    • АТХ:

    L.01.X.C.12   Brentuksimab vedotin

    Pharmacodynamics:

    A conjugate of a monoclonal antibody with an antitumor agent delivered to tumor cells that express the antigen CD30. After binding of the antigen, the conjugate penetrates into the cell by endocytosis, then is transported by lysosomes. Inside the cell, an active ingredient is released - monomethylauristatin, which binds to tubulin, which leads to the destruction of the microtubule network. As a result, the cell cycle is inhibited, which leads to the death of the CD30-expressing tumor cell.

    As a result of their interaction, selective apoptosis of the tumor cell takes place.

    Pharmacokinetics:

    After intravenous administration, the elimination half-life is 4-6 days. The connection with plasma proteins is 80%.

    Metabolism in the liver. Elimination by the kidneys.

    Indications:

    It is used to treat Hodgkin's lymphoma. Used for relapsing or refractory anaplastic large-cell lymphoma.

    ICD-10

    II.C81-C96.C81   Hodgkin's disease [lymphogranulomatosis]

    II.C81-C96.C84   Peripheral and cutaneous T-cell lymphomas

    Contraindications:

    Simultaneous use with bleomycin, age under 18, pregnancy and lactation,individual intolerance.

    Carefully:Diabetes mellitus, hepatic insufficiency, hypersensitivity.

    Pregnancy and lactation:Contraindicated in pregnancy and lactation.
    Dosing and Administration:

    Intravenously slowly (within 30 minutes) at 1.8 mg / kg every 3 weeks; within one year - 8-16 cycles of treatment.

    The highest daily dose: 1.8 mg / kg.

    The highest single dose: 1.8 mg / kg.

    Side effects:

    Central and peripheral nervous system: dizziness, peripheral sensory and motor neuropathy, polyneuropathy, progressive multifocal leukoencephalopathy.

    Respiratory system: cough, upper respiratory tract infection, pneumonia.

    Hemopoietic system: anemia, neutropenia, thrombocytopenia.

    Digestive system: nausea, vomiting, diarrhea, constipation, rarely - acute pancreatitis.

    Musculoskeletal system: arthralgia, back pain, myalgia.

    Dermatological reactions: rash, itching, alopecia, Stevens-Johnson syndrome.

    Allergic reactions.

    Overdose:

    Cases of overdose are not described.

    Treatment is symptomatic.

    Interaction:

    At simultaneous application with ketoconazole the risk of development of a neutropenia is amplified.

    Rifampicin reduces the action of Brentuksimab vedotin up to 31%.

    Special instructions:

    During treatment, patients need to use reliable contraceptive methods, as well as within 6 months after treatment. When taking the drug is not recommended driving and working with moving machinery.

    Instructions
    Up